All In Biotech

Drug Trial Radar · NCT05872347

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

A Phase II Study of SPH4336 in Combination With Endocrine Therapy in HR-positive, HER2-negative Breast Cancer Patients With Brain Metastases.

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

52

Planned (sponsor's estimate)

Start

Sep 19, 2023

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Sponsor type
Industry
First posted
May 24, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.

Conditions

  • Breast Cancer Brain Metastases

Interventions

  • SPH4336 TabletsDrug

    SPH4336 Tablets :Administered by oral; Letrozole tablets:Administered by oral; Fulvestrant injection:Administered by intravenous infusion; Exemestane:Administered by oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intracranial Objective response rate(iORR)Time frame: Approximately 3 years

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, China · Recruiting

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, China · Recruiting

  • Chongqing University Three Gorges Hospital

    Chongqing, China · Recruiting

  • Guangxi Medical University Cancer Hospital & Guangxi Cancer Institute

    Nanning, China · Recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Xi'An International Medical Cancer Hospital

    Xi'an, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, China · Recruiting

  • Anhui provincial hospital

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Affiliated Cancer Hospital, Sun Yat-sen University

    Guangzhou, Guangdong, China · Recruiting

  • Liuzhou people's Hospital

    Liuzhou, Guangxi, China · Recruiting

  • Anyang Cancer Hospital

    Anyang, He'nan, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, He'nan, China · Recruiting

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China · Recruiting

  • Harbin Medical University cancer Hospital

    Harbin, Heilongjiang, China · Recruiting

  • Xiangyang Central Hospital

    Xiangyang, Hubei, China · Recruiting

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, China · Recruiting

  • The second people's hospital of neijiang

    Neijiang, Sichuan, China · Recruiting

  • Cancer Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang, China · Recruiting

  • Zhejiang cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.